Landscape of somatic alterations in large-scale solid tumors from an Asian population

Liqun Wu, Herui Yao, Hui Chen, Aodi Wang, Kun Guo, Wenli Gou, Yanfei Yu, Xiang Li, Ming Yao, Shaohua Yuan, Fei Pang, Jinwei Hu, Lijuan Chen, Wenjin Liu, Jicheng Yao, Shuirong Zhang, Xiaowei Dong, Weifeng Wang, Jing Hu, Qi Ling, Songming Ding, Yan Wei, Qiang Li, Weichun Cao, Shuang Wang, Yang Di, Feiling Feng, Gang Zhao, Jian Zhang, Ling Huang, Jia Xu, Wangjun Yan, Zhongsheng Tong, Da Jiang, Tao Ji, Qiao Li, Ling Xu, Huiying He, Liang Shang, Jin Liu, Kefeng Wang, Duoguang Wu, Jingnan Shen, Ye Liu, Ting Zhang, Chaojie Liang, Yusheng Wang, Yanhong Shang, Jianji Guo, Guanbiao Liang, Shifeng Xu, Junfeng Liu, Kai Wang () and Minghui Wang ()
Additional contact information
Liqun Wu: Affiliated Hospital of Qingdao University
Herui Yao: Sun Yat-Sen University
Hui Chen: Shanghai OrigiMed Co., Ltd
Aodi Wang: Shanghai OrigiMed Co., Ltd
Kun Guo: Fudan University
Wenli Gou: First Affiliated Hospital of Xi’an Jiao Tong University
Yanfei Yu: Shanghai OrigiMed Co., Ltd
Xiang Li: Shanghai OrigiMed Co., Ltd
Ming Yao: Shanghai OrigiMed Co., Ltd
Shaohua Yuan: Shanghai OrigiMed Co., Ltd
Fei Pang: Shanghai OrigiMed Co., Ltd
Jinwei Hu: Shanghai OrigiMed Co., Ltd
Lijuan Chen: Shanghai OrigiMed Co., Ltd
Wenjin Liu: Shanghai OrigiMed Co., Ltd
Jicheng Yao: Shanghai OrigiMed Co., Ltd
Shuirong Zhang: Shanghai OrigiMed Co., Ltd
Xiaowei Dong: Shanghai OrigiMed Co., Ltd
Weifeng Wang: Shanghai OrigiMed Co., Ltd
Jing Hu: The First People’s Hospital of Yunnan Province
Qi Ling: Zhejiang University
Songming Ding: Shu Lan (Hangzhou) Hospital
Yan Wei: The Eighth Affiliated Hospital of Guangxi Medical University
Qiang Li: Affiliated Hospital of North Sichuan Medical University
Weichun Cao: Central South University
Shuang Wang: Southern Medical University
Yang Di: Fudan University
Feiling Feng: Shanghai Eastern Hepatobiliary Surgery Hospital
Gang Zhao: Tianjin Medical University Cancer Institute and Hospital
Jian Zhang: Huazhong University of Science and Technology
Ling Huang: Huifuxi Branch of Guangdong Provincial People’s Hospital
Jia Xu: Sun Yat-sen University
Wangjun Yan: Fudan University
Zhongsheng Tong: Tianjin Medical University Cancer Institute and Hospital
Da Jiang: Fourth Hospital of Hebei Medical University
Tao Ji: Peking University
Qiao Li: Chinese Academy of Medical Sciences and Peking Union Medical College
Ling Xu: Peking University First Hospital
Huiying He: Peking University
Liang Shang: Shandong Provincial Hospital Affiliated to Shandong University
Jin Liu: Shandong Provincial Hospital Affiliated to Shandong University
Kefeng Wang: Sun Yat-sen University
Duoguang Wu: Sun Yat-sen University
Jingnan Shen: Sun Yat-sen University
Ye Liu: Sun Yat-sen University
Ting Zhang: Zhejiang University
Chaojie Liang: The First Hospital of Shanxi Medical University
Yusheng Wang: Shanxi Provincial Cancer Hospital
Yanhong Shang: Hebei University
Jianji Guo: First Affiliated Hospital of Guangxi Medical University
Guanbiao Liang: First Affiliated Hospital of Guangxi Medical University
Shifeng Xu: Shandong Provincial Hospital Affiliated to Shandong University
Junfeng Liu: Fourth Hospital of Hebei Medical University
Kai Wang: Shanghai OrigiMed Co., Ltd
Minghui Wang: Sun Yat-Sen University

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-31780-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31780-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-31780-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().